Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Yarden

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Oncogene|April 18, 1998
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulinR Pinkas-Kramarski, A E Lenferink, S S Bacus, et al.
Nature|September 18, 1986
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptorsY Yarden, J A Escobedo, W J Kuang, et al.
The EMBO Journal|June 17, 1998
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersA E Lenferink, R Pinkas-Kramarski, M L van de Poll, et al.
The Journal of Biological Chemistry|May 30, 1998
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexesM Shelly, R Pinkas-Kramarski, B C Guarino, et al.
The EMBO Journal|August 15, 1997
Bivalence of EGF-like ligands drives the ErbB signaling networkE Tzahar, R Pinkas-Kramarski, J D Moyer, et al.
Molecular and Cellular Biology|December 28, 1999
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathwayR J Lee, C Albanese, M Fu, et al.
Oncogene|May 9, 2007
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signalingK Shtiegman, B S Kochupurakkal, Y Zwang, et al.
Oncogene|June 20, 1996
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cellsS S Bacus, Y Yarden, M Oren, et al.
Oncogene|July 12, 2011
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal fillingC-R Pradeep, W J Köstler, M Lauriola, et al.
Oncogene|December 6, 2011
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC-R Pradeep, A Zeisel, W J Köstler, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Oncogene|April 18, 1998
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulinR Pinkas-Kramarski, A E Lenferink, S S Bacus, et al.
Nature|September 18, 1986
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptorsY Yarden, J A Escobedo, W J Kuang, et al.
The EMBO Journal|June 17, 1998
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersA E Lenferink, R Pinkas-Kramarski, M L van de Poll, et al.
The Journal of Biological Chemistry|May 30, 1998
Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexesM Shelly, R Pinkas-Kramarski, B C Guarino, et al.
The EMBO Journal|August 15, 1997
Bivalence of EGF-like ligands drives the ErbB signaling networkE Tzahar, R Pinkas-Kramarski, J D Moyer, et al.
Molecular and Cellular Biology|December 28, 1999
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathwayR J Lee, C Albanese, M Fu, et al.
Oncogene|May 9, 2007
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signalingK Shtiegman, B S Kochupurakkal, Y Zwang, et al.
Oncogene|June 20, 1996
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cellsS S Bacus, Y Yarden, M Oren, et al.
Oncogene|July 12, 2011
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal fillingC-R Pradeep, W J Köstler, M Lauriola, et al.
Oncogene|December 6, 2011
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesionsC-R Pradeep, A Zeisel, W J Köstler, et al.
Pageof 17